Ignite Creation Date:
2025-12-25 @ 2:11 AM
Ignite Modification Date:
2026-01-04 @ 9:48 PM
Study NCT ID:
NCT07038460
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-06-26
First Post:
2025-06-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
Sponsor:
Wen-zhao ZHONG
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-07
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12
Completion Date Type:
ESTIMATED
First Submit Date:
2025-06-18
First Submit QC Date:
None
Study First Post Date:
2025-06-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-18
Last Update Post Date:
2025-06-26
Last Update Post Date Type:
ACTUAL